Medtronic’s (MDT) Buy Rating Reiterated at TD Cowen

TD Cowen reiterated their buy rating on shares of Medtronic (NYSE:MDT) in a report published on Wednesday, Marketbeat reports. The firm currently has a $110.00 price objective on the medical technology company’s stock.

Several other equities research analysts have also recently issued reports on MDT. Royal Bank Of Canada reiterated an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Weiss Ratings upgraded Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. Evercore set a $105.00 target price on Medtronic in a research report on Monday, July 6th. Finally, Truist Financial reissued a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic Price Performance

Shares of Medtronic stock opened at $86.31 on Wednesday. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The company has a 50-day simple moving average of $90.15 and a two-hundred day simple moving average of $84.79. The stock has a market capitalization of $110.40 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 1.97 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the previous year, the firm posted $1.26 EPS. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts forecast that Medtronic will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is currently 70.94%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Medtronic

A number of institutional investors have recently modified their holdings of MDT. Ipsen Advisor Group LLC raised its position in shares of Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after buying an additional 101 shares in the last quarter. Arlington Trust Co LLC grew its position in Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after acquiring an additional 120 shares in the last quarter. Bigelow Investment Advisors LLC grew its position in Medtronic by 1.1% in the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after acquiring an additional 121 shares in the last quarter. Bank & Trust Co increased its stake in Medtronic by 2.8% in the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after acquiring an additional 121 shares during the last quarter. Finally, Integrity Alliance LLC. increased its stake in Medtronic by 1.7% in the second quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after acquiring an additional 125 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen reiterated a “Buy” rating on Medtronic, providing an analyst-confidence signal for the medical-device maker. Medtronic Earns Buy Rating from TD Cowen
• Positive Sentiment: The FDA granted breakthrough-device designation to Medtronic’s below-the-knee drug-coated balloon, potentially accelerating regulatory interaction and supporting the company’s peripheral vascular pipeline. Medtronic Receives Breakthrough Designation
• Positive Sentiment: The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation device and Symplicity Spyral renal-denervation system. The codes become effective in January 2028 and could improve reimbursement visibility and adoption over the long term. Medtronic CPT Code Approvals
• Positive Sentiment: New regulatory clearances for cardiac mapping and ablation software may strengthen Medtronic’s competitive position in the growing pulsed-field ablation market. Medtronic Cardiac Software Clearances
• Neutral Sentiment: A commentary argues that Medtronic’s dividend and defensive healthcare exposure could remain attractive if inflation and interest rates stay elevated, but it does not represent a new company-specific catalyst. Inflation and Dividend Stocks
• Neutral Sentiment: An investment opinion says Medtronic’s long-term strategy could still appeal to investors, although Johnson & Johnson’s stronger historical performance highlights execution concerns. Johnson and Johnson Compared With Medtronic
• Negative Sentiment: The $4 billion tax-free MiniMed exchange offer appears to be losing investor appeal. Reduced participation could make the split-off a weaker near-term catalyst and leave shareholders focused on execution and valuation risks. Medtronic MiniMed Exchange Offer
• Negative Sentiment: Medtronic’s stock has declined since its latest earnings report, with investors apparently looking for stronger forward earnings momentum despite the prior quarterly revenue and EPS beat. Medtronic Stock Since Earnings
• Negative Sentiment: Put-option volume was about 45% above average, indicating increased downside hedging or bearish positioning around MDT.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.